Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imbruvica in Relapsed or Refractory Marginal Zone Lymphoma
NCT03093831Phase 2Terminated
- Sponsor
- National Cancer Centre Singapore
- Start
- Jul 2016
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ibrutinib in marginal zone lymphoma (MZL), sponsored by National Cancer Centre Singapore. Started Jul 2016; status: terminated.
02
Drugs
ibrutinib
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT03093831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03093831.